July 27, 2021

This Little Diagnostic Went To Market...

This Little Diagnostic Went To Market...

On the show today: Liz Cormier-May, CEO of Mammogen, and Marty Keiser, CEO at IV Bioholdings, who share their thoughts and commercial insights on the diagnostics market including the challenges in getting more affordable and accessible diagnostics reaching patients.

On the show today, I'm thrilled to welcome – LIVE IN STUDIO — Liz Cormier-May, CEO of Mammogen, and Marty Keiser, CEO at IV Bioholdings. It's hard to blend funny, entertaining wit with healthcare jargon like diagnostics, market access, go-to-market strategy, etc. And yet, somehow, we did it. The process is gnarly and ridiculous but, now more than ever, it's actually possible to NOT GET CANCER because of much more accessible and affordable diagnostics. Some of them are free; some are even over the counter. But getting into the hands of doctors or retail consumers is a whole other story, let alone issues with the FDA and safety. Well, we cut through all that crap and get to the brass taxes of how the only real thing moving the needle are consumers who vote with their wallets.

For more information, visit https://OffScripMedia.com and follow @MZOutofPatients, @MatthewZachary, @VaxOnPod, and @OffScripMedia on Twitter.


See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.